Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

Prices for the top 25 brand-name Medicare Part D drugs have increased by an average of 98% since entering the market, ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering ...

Naturally, more work is needed. Although GLS -1 agonists have been used in diabetes for 20 years, some of the newer findings ...

Concurrently, a preprint from the industry-backed Vital Transformation found a 50% drop in company investments into ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

College costs have been on a mostly upward trend for the last two decades. In addition to rising tuition prices, paying for housing, food, transportation, textbooks and other school-related fees ...

Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...

Given that more than 40% of Indian adults are struggling with obesity and diabetes, affordable weight-loss drugs are expected ...

NDAQ:VKTX) Viking Therapeutics Announces Initiation of Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity ...

Weight-loss medication like Semaglutide and Tirzepatide has seen a rise in demand, causing a boom in sales. This exploding ...